skip to Main Content

Global University Venturing features MaRS Innovation’s unique model for technology transfer

Dr. Raphael Hofstein
Dr. Raphael Hofstein, president & CEO, MaRS Innovation.

MaRS Innovation’s “model solves the two weakest points in tech transfer: the lack of dealflow and the ability to match public funding,” writes Thierry Heles in, “MaRS Innovation: A Unique Model for Tech Transfer,” for Global University Venturing.

This feature was also covered in Techopia.

The article, which includes an interview with Dr. Rafi Hofstein, president and CEO of MaRS Innovation, was published September 14, 2015.

Here’s an excerpt exploring the range of MI’s portfolio and Hofstein’s strategy for addressing technologies emerging in new areas:

In the beginning, Mars received primarily discoveries in the medical sector, but the balance has since shifted to 60% medically-oriented research and 40% for other areas. The medically-oriented discoveries, Hofstein elaborated, are a diverse set of technologies and include everything from drug development and molecular diagnostics to medical devices and healthcare IT.

The remaining 40% meanwhile cover “a smörgåsbord all the way from alternative energies and solar energy, and water reclamation to all sorts of mobile apps”.

Continue Reading

Tech Transfer Central features MaRS Innovation’s partnership with St. Michael’s Hospital

St. Michael's Hospital LogoTech Transfer Tactics, the monthly newsletter for Tech Transfer Central.com, has published a feature highlighting MaRS Innovation’s Technology Transfer & Scouting (MITTS) services to St. Michael’s Hospital.

The interview explores the increase in disclosures and commercial activity achieved after MaRS Innovation began offering technology transfer services to the hospital, and was triggered by a July profile published on MaRS Innovation’s website describing the collaborative working relationship between the two organizations.

The interview includes conversations with Sahail Shariff, commercialization manager in the MITTS division, and Samar Saneinejad, director of strategic projects in the Office of the Vice President of Research at St. Michael’s, explores the success

Here’s an excerpt:

MaRS Innovation, a member institution of the Networks of Centres of Excellence of Canada, has dramatically increased invention disclosures at St. Michael’s Hospital in Toronto by providing hospital researchers with an embedded technology transfer expert who offers commercialization guidance and access to other vital tech transfer resources.

Continue Reading

MaRS Innovation Industry Access Program (MI-IAP) accepting applications until April 10

Researchers working in orphan indications, drug delivery devices, big data and other key areas invited to submit a brief Statement of Interest

The commercialization process: Moving transformational ideas from the lab bench to the street
MaRS Innovation’s commercialization process helps inventors move their transformational ideas from the lab bench to the street.

The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI’s industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and Merck.

The program’s goal is to secure funding for researchers within MI’s membership through these collaborative, strategic R&D partnership programs.

First run in November 2013, the MI-IAP allows researchers to easily determine whether an industry partner is interested in co-developing their technologies. The application process is deliberately brief at the outset.

Ben Rogers
Ben Rogers, director, technology transfer & scouting

“Last fall, we received 28 statements of interest, 12 of which we invited to submit a non-confidential summary package,” said Ben Rogers, director, Technology Transfer & Scouting. “Of these, six have been invited for a technology presentation with an industry partner. We’d like to see all of those numbers grow during this application round.”

The program will also make it easier for researchers to find prospective industry partners.

Continue Reading

Dr. Raphael (Rafi) Hofstein joins Quebec’s CQDM Board of Directors

Dr. Raphael Hofstein
Dr. Raphael Hofstein has joined the Quebec Consortium for Drug Discovery (CQDM) Board of Directors.

MaRS Innovation’s President and CEO, Dr. Raphael (Rafi) Hofstein, was appointed to the Quebec Consortium for Drug Discovery (CQDM) Board of Directors on February 18.

CQDM is a Quebec-based not-for profit that funds and supports joint projects in private and biopharmaceutical sectors.

Here’s an excerpt from CQDM’s announcement:

Dr. Hofstein, actively involved in the field of biotechnology, partnerships and technology transfer for over 30 years, greatly contributed to defining Israel as a world leader in biotechnology. In Israel, Dr. Hofstein held various positions including R & D Manager and Chief of Immunochemistry with the International Genetic Scientific Partnership, Scientific Director at Biotechnological Applications Ltd., Scientific Director and Vice-President, Business Development at Ecogen Inc., prior to becoming President of Mindsense Biosystems Ltd., and then founder, President and CEO, and chairman of the Board of Hadasit Ltd.

CQDM

Dr. Hofstein was also president of BIOMED, the annual biomedical conference of Israel for many years. He was also co-founder and member of the Israeli Life Sciences Industry Organization and co-founder and executive of Israel’s Tech Transfer Network. Dr. Hofstein now serves on various boards, including Life Sciences Ontario, Clinical Trials Ontario as well as the Organizing Committee of the Public Policy Forum on venture capital and innovation. Dr. Hofstein holds a Ph.D. in the life sciences and chemistry, and completed his postdoctoral studies at the Harvard Medical School.

Continue Reading

Johnson & Johnson Innovation Announces Collaborations with Two Canadian Early-Stage Drug Technology Development Centers

The commercialization process: Moving transformational ideas from the lab bench to the street
MaRS Innovation’s commercialization process helps inventors move their transformational ideas from the lab bench to the market.

Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada announced new collaborations with two Canadian early-stage drug technology development centres, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health.

Read the original release via The National Post or in French. MaRS Innovation’s November 25 announcement about the partnership is also available.

This story was covered by GEN: Genetic Engineering Biotechnology News.

Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will work with NEOMED and MaRS Innovation to identify investment opportunities emerging from well-validated scientific research discoveries within their communities of academic institutions and biotechnology companies.

Continue Reading

MaRS Innovation launches streamlined funding program

Applications invited for MI’s Industry Access Program, which matches early-stage, high-potential technologies to partners and funding

The commercialization process: Moving transformational ideas from the lab bench to the street
MaRS Innovation’s commercialization process helps inventors move their transformational ideas from the lab bench to the street.

MaRS Innovation (MI) has launched a unique funding program to match researchers with industry partners while advancing early stage technologies: the MaRS Innovation Industry Access Program (MI-IAP).

This program provides a simple mechanism to connect researchers with MI’s industry partners. The process and application form are intentionally brief to save researchers time and allow MI’s partners to review a wide range of remarkable technologies within the Toronto academic community in a short period of time.

ParimalNathwani8757
Parimal Nathwani, vice-president, Life Sciences,     MaRS Innovation.

“Many granting programs require an industry partner, but leave finding that partner to the researcher,” says Parimal Nathwani, vice-president of life sciences at MI. “Our Industrial Partnership Program completes that step for them. We also know researchers within our member institutions are incredibly busy, which is why we’ve adopted a streamlined process to save them time.”

The program is open to any researcher affiliated with our 16 member institutions working on technologies in:

  • therapeutics
  • diagnostics
  • medical devices
  • health IT
Continue Reading

Five UTEST companies to tackle critical healthcare challenges

Program’s second cohort includes eQOL, E-Twenty Development, Root2Crown, Treata Smart Solutions and TrendMD

University of TorontoTORONTO (May 14, 2013) — Five companies tackling pervasive healthcare challenges — such as assessing dental health, helping patients and medical personnel navigate hospitals with greater ease, staying current with medical literature, or creating digital tools to help care for the elderly or those with chronic health conditions — have been admitted to the University of Toronto Early Stage Technology (UTEST) program’s second cohort.

UTEST, supported by the University of Toronto’s Connaught Fund, Innovations & Partnerships Office (IPO) and MaRS Innovation (MI), is part of a growing system of incubators and commercialization support services at U of T.

Two companies in UTEST’s second cohort, E-Twenty Development Inc. and Treata Smart Solutions Inc. are participating in Canada 3.0 at the Metro Convention Centre May 14 and 15, 2013, in Toronto.

This announcement was covered in PE Hub.

Each company will receive up to $25,000, incubation space in the MaRS Discovery District, mentoring and business strategy support to develop protectable intellectual property, launch their products and gain market traction. They are also eligible to become clients of MaRS Discovery District’s ICE or Healthcare practices.

UTEST seeks scalable, enterprise-focused software applications interested in building business-to-business customer bases — and preferably operational products with a short term to market. The program is co-directed by Kurtis Scissons (U of T IPO) and Dr. Lyssa Neel (MI).

The second cohort has big shoes to fill. UTEST’s first cohort has collectively secured over $1.2 million in follow-on funding and currently employs 29 highly skilled people (HQPs). Each company also filed solid patent protection and most have secured customers. Notably, Whirlscape’s Indiegogo campaign secured over $87,000 in crowd-sourced product funds from nearly 10,000 users, and was featured in the Financial Post, TechCrunch, Mashable and The Verge, among other global media outlets.

Continue Reading

MaRS Innovation awarded $15 million to further commercialize world-leading Canadian innovations

Networks of Centres of Excellence recognizes strength of partnership between MI and its 16 member institutions

Networks of Centres of Excellence logoTORONTO, February 5, 2013 — How do you make sure the brilliant ideas emerging from Toronto’s academic research community get the best possible chance to succeed?

MaRS Innovation (MI), created in 2008, bridges the chasm between these early-stage technologies and successful start-up companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, mentorship and IP strategy protection, MI acts as a commercialization agent for its 16 member institutions.

This announcement was covered by TechVibes, Yonge Street Media and CanTech Letter.

The Networks of Centres of Excellence (NCE) has recognized the increasing strength of this novel partnership by awarding MI $14.95 million in funding through the Centres of Excellence for Commercialization and Research (CECR) program.

Continue Reading

Raphael Hofstein gives guest lecture on biotechnology commercialization at Stanford

Raphael Hofstein
Raphael Hofstein, president and CEO of MaRS Innovation

Dr. Raphael Hofstein, president and CEO of MaRS Innovation, delivered a guest lecture on February 1,2013 at the Revitalizing Medical BioTechnology Commercialization symposium, hosted by Stanford University‘s NIH Graduate Training Program in Biotechnology.

The one-day event brought academic, venture capital and industry thought leaders together to reflect on the challenges facing technology transfer processes across the biotech industry.

Continue Reading
Back To Top